18 results about "Hematologic disease" patented technology

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The invention relates to the technical field of medical equipment, in particular to a portable diagnosis and treatment instrument for blood disease treatment, which comprises a box body and moving wheels, an opening is formed in the upper end of the box body, locking openings are formed in two sides of the top of the box body, and the moving wheels are mounted on the box body; the partition plate is fixedly mounted in the middle of the box body; the access mechanism is installed on the box body, the control end of the access mechanism is arranged outside the box body, and the power output end of the access mechanism is fixedly connected with diagnosis and treatment equipment; the outward pushing mechanisms are fixedly installed on the two sides of the partition plate, extending mechanisms penetrate through the outward pushing mechanisms on the two sides, and one ends of the extending mechanisms are connected with the diagnosis and treatment equipment; the box cover is matched with the opening of the box body, rotary knobs are rotationally installed on the two sides of the box cover, and clamping plates are fixedly arranged on the rotary knobs; and the handle is fixedly mounted on the box cover. The portable diagnosis and treatment instrument for blood disease treatment provided by the invention not only can diagnose and treat blood diseases, but also has better portability, meanwhile, diagnosis and treatment equipment can be quickly taken out or put into the box body, the operation is simple, and the practicability is high.

The invention relates to a sepsis progress risk prediction method and system for a hematological deficiency patient. The method comprises the following steps: controlling a sepsis sequencing platform to perform transcriptome sequencing on peripheral blood to obtain clean gene sequence data; identifying abnormal genome concentration corresponding to sepsis in the clean gene sequence data; and inputting the abnormal genome concentration into the abnormal progress risk prediction model corresponding to sepsis to obtain abnormal progress risk prediction data. By adopting the method, early risk prediction can be realized.

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The invention discloses a blood disease marrow fluid sample collection device, and belongs to the technical field of medical instruments, the device comprises a collection main body, a first piston assembly, a second piston assembly and a filter assembly, the collection main body is internally provided with a first chamber; the first piston assembly is arranged in the first cavity, the second cavity is formed in a piston rod body of the first piston assembly, the second piston assembly is arranged in the second cavity, and the second cavity and the first cavity are connected through a second cavity communicating channel; the filtering assembly is arranged at the front end of the communicating channel of the second cavity, after the first piston assembly is driven to extract marrow fluid into the first cavity, the collecting body is removed from the puncture needle, and the second piston assembly is driven to suck the marrow fluid in the first cavity into the second cavity; the bone marrow particle tissue in the bone marrow fluid in the first cavity is collected through the filter screen, separated collection of the bone marrow fluid and the bone marrow particles is completed, the complete structure of the bone marrow particles can be guaranteed, and the collection efficiency is higher.

The utility model provides a blood disease chemotherapy patient skin care device which comprises a care device bottom plate, a connecting plate is fixedly arranged on one side of the top end of the care device bottom plate, a control handle is installed at the top end of the connecting plate, the control handle is in an L shape and can be conveniently held by medical staff, and a heat dissipation plate is fixedly arranged at one end of the care device bottom plate. According to the scheme, the medicine spraying plate is controlled to be started by pressing the control button, at the moment, the medicine spraying plate is started, the atomization spray head is turned on and turned off, and nursing liquid medicine in the storage disinfection tank is atomized outwards through the atomization spray head and applied to the positions, where symptoms occur, such as swelling, itching, dryness, desquamation and even ulceration, of the skin surface of a patient; and the skin care work of medical personnel is facilitated.

The invention relates to the field of chemotherapy toxicity prediction modeling, in particular to a construction method of a blood disease chemotherapy toxicity prediction model. According to the method, the dynamic metabolic coefficient of a patient to be detected is obtained according to the change of absolute neutrophil count of the patient to be detected after current chemotherapy and the albumin content and bilirubin level after current chemotherapy, and the injury coefficient of the patient to be detected is obtained according to the medication dosage and toxicity level of the patient to be detected in current chemotherapy. Obtaining a toxicity accumulation coefficient of the patient to be detected in the current chemotherapy by combining the content of the toxicity detection marker before the previous chemotherapy and the drug exposure dose of the current chemotherapy, constructing a bone marrow state vector and a liver state vector, and adjusting the liver state vector to obtain an adjusted liver state vector of the patient to be detected in the current chemotherapy; and constructing a chemotherapy toxicity prediction model by combining the multi-modal data of all patients in all historical chemotherapy periods. According to the method, the accurate chemotherapy toxicity prediction model can be established, and the chemotherapy toxicity prediction deviation is reduced.

The present application relates to the technical field of blood extraction, in particular to a cell separation and extraction device for animal blood disease detection, which comprises a box body, a partition plate is arranged at the bottom of the box body, a cavity is formed between the box body and the partition plate, a centrifugal assembly is arranged in the cavity, and the centrifugal assembly is used for placing test tubes for centrifugal operation, the test tubes after centrifugation are taken out and replaced by collection test tubes, the piston rod at the end of the air cylinder drives the rack to reciprocate in the vertical direction, the rack drives the double-head gear rod to mesh and rotate in the moving process, the double-head gear rod drives the second wedge-shaped plate to reciprocate at a 90° angle in the rotating process, so that the second wedge-shaped plate reciprocally extrudes the first wedge-shaped plate, the air in the rubber head of the suction tube is continuously sprayed out, in the process of air spraying to generate airflow, the airflow pushes and extrudes the cell liquid temporarily stored in the glass tube of the suction tube, so that the cell liquid enters the collection test tube for collection, and the accuracy of animal pathological detection is improved.

The application discloses a kind of based on microfluidic and AI image recognition basophil activation detection method and system.The method comprises: the peripheral blood sample to be measured is injected into the microfluidic chip device containing conical microporous filter membrane and enriched basophil;In reaction cavity, pre-mixed dry CD63-FITC and CD203c-PE fluorescently labeled antibody and allergen stimulant are added;After incubation at 37 DEG C, 512×512 pixel high-resolution image is obtained by digital microscopic imaging system;Improved target detection model is used to identify activated cells, the model uses lightweight FasterNet backbone network and dynamic attention mechanism, generates cell activation heat map by Gaussian kernel density estimation, combines fluorescence intensity weighted calculation activation index and outputs visual report.System includes microfluidic chip module, fluorescently labeled module, temperature control incubation module, image acquisition module, AI analysis module and man-machine interaction module.The application realizes high sensitivity, high specificity and automatic detection, and is suitable for clinical diagnosis of allergic diseases and blood diseases.

A construction method of a blood disease knowledge graph database is characterized by comprising the following steps: determining a target user and a purpose of the database, and defining a concept and a relationship of a blood disease field; blood disease field data are collected and preprocessed; using a natural language processing technology to extract entities, relationships and attributes in the blood disease data text, and establishing relationships among the entities; establishing a blood disease ontology model and designing a database; storing the processed data in a database, designing query and retrieval interfaces, and supporting a user to query and browse a knowledge graph; and verifying the accuracy and integrity of the knowledge graph. According to the method, through the accurate entities and the relation model, the relation among the entities such as diseases, symptoms and treatment methods in the knowledge graph is clearer. The method is helpful for users to better understand related knowledge of blood diseases, and supports clinical decision and research. An effective updating mechanism is constructed, and it is ensured that information in the knowledge graph is synchronized with the latest medical research progress and clinical practice.

The application provides an antibody composition for detecting acute T lymphoblastic leukemia by full-spectrum flow cytometry, a detection system and application thereof, and relates to the technical field of blood disease detection. The antibody composition is two groups of antibodies. The first group is 14 kinds of fluorescein-labeled cell membrane monoclonal antibodies, including anti-CD45, anti-CD99, anti-CD34, anti-CD48, anti-CD2, anti-CD3, anti-CD4, anti-CD5, anti-CD7, anti-CD8a, anti-CD16, anti-CD56, anti-CD94 and anti-TCR gamma delta. The second group is two kinds of intracellular monoclonal antibodies, including anti-nucleus TdT and anti-cytoplasm CD3. The two groups of antibodies are added into the same tube in sequence. The application also provides a flow cytometry sample for detecting acute T lymphoblastic leukemia based on full-spectrum flow cytometry, and a detection analysis method and system, so that the missed diagnosis rate and misdiagnosis rate of T-ALL detection are reduced.

The invention relates to a method for determining path data influencing the progress of malignant blood particle deficiency type sepsis. The method comprises the following steps: filtering initial gene sequence data to obtain clean gene sequence data; performing gene quantitative analysis on the clean gene sequence data to obtain gene expression quantity data; performing gene differential expression analysis on the gene expression quantity data to obtain differential expression gene data; and performing function enrichment analysis on the differential expression gene data to obtain significant enrichment pathway data. By adopting the method, the path data can be determined to have novelty and specificity.

The application provides a freezing optimization method of a human blood disease sample and a method for establishing a PDX animal model by using a human blood sample, and relates to the technical field of PDX model construction. The application specifically relates to a method for optimizing and improving long-term freezing of a human blood disease sample, and a method for optimizing and improving establishment of a blood disease PDX model, so that the success rate of establishing a PDX animal model by using a clinical blood disease sample after freezing and recovery is greatly improved. The method can be used for long-term storage of blood disease patient samples, and storage of rare and valuable samples such as drug-resistant and relapsed samples; meanwhile, the method can solve existing clinical problems such as long-distance patient sample transportation difficulties, and has short modeling time and high modeling rate.

Provided herein are antibodies, compositions, and methods of use thereof. The disclosed antibodies bind to a von Willebrand factor in the plasma of a subject. Such antibodies are useful in methods of treatment, such as methods of treating one or more blood conditions characterized by excessive bleeding.

This invention proposes a method and system for prognostic analysis of hematological stem cell transplantation based on OCR and NLP technologies. The method includes receiving and recognizing medical reports uploaded by users, recognizing them as raw text through an OCR service, and then converting them into medical text through post-processing. Subsequently, an NLP service is invoked to extract structured patient features, which are then optimized and input into a prognostic prediction model to obtain prediction results for various prognostic indicators. Finally, the outputs of multiple models are merged to generate a visualized prediction report. This invention achieves seamless data linkage and automated flow between modules without human intervention by constructing a fully automated collaborative architecture that integrates medical data uploading, OCR recognition, structured data extraction, AI prognostic prediction, and result output. This eliminates data breakpoints and human errors, solving the technical problems of isolated functional modules and data flow breakpoints in existing technologies. Furthermore, it improves adaptability to medical scenarios.

The invention relates to the technical field of biomedical engineering, in particular to an infusion monitoring and adjusting system for child blood disease chemotherapy medicine infusion, which comprises a data acquisition module, a flow velocity analysis module, a pressure analysis module and a flow velocity adjusting module. Determining a flow velocity decline analysis time period based on the decline condition of the flow velocity data, and determining a pressure decline mitigation degree based on the change condition of the pressure data in the flow velocity decline analysis time period; and the flow rate during medicine infusion is adjusted on the basis of the pressure drop relaxation degree and the drop degree of the flow rate data in the flow rate drop analysis time period. The flow speed during medicine infusion is adjusted in a self-adaptive mode under the condition that the resistance can be adjusted, and the medicine infusion adjusting precision is effectively improved.

Provided are chimeric molecules, compositions, and applications thereof that specifically bind to natriuretic peptide receptor C (NPR-C). The disclosed chimera comprises an NPR-C binding domain and a target-binding domain. Through NPR-C-mediated endocytosis, the chimera enables the intracellular degradation of the target by lysosomal enzymes. The chimeric molecules can rapidly, conveniently, and precisely degrade target proteins. Their modular design permits broad applicability to proteins such as secreted proteins and membrane-associated proteins. These chimeric molecules exhibit high bioavailability and low immunogenicity, thus being broadly applicable for the treatment of diseases including cancer, neurodegenerative diseases, psychiatric disease, central nervous system diseases, inflammatory diseases, autoimmune diseases, metabolic syndrome, tissue fibrotic disease, cardiovascular diseases, respiratory diseases, digestive diseases, renal diseases, hematologic diseases, infectious diseases, rare diseases and aging-related disease.